theralase_logo_destroying_cancer.png
Theralase® Launches Seventh US-Based Clinical Study Site and Treats First Patient in the US
June 11, 2021 07:00 ET | Theralase Technologies Inc.
TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
AB Science today announced that results from masitinib study AB12005 in pancreatic cancer have been presented at the 2021 ASCO Annual Meeting
June 10, 2021 12:54 ET | AB Science
PRESS RELEASE RESULTS FROM MASITINIB STUDY AB12005 IN PANCREATIC CANCER PRESENTED AT THE ASCO ANNUAL MEETING WITH THE FULL ABSTRACT PUBLISHED IN THE JOURNAL OF CLINICAL ONCOLOGY Paris, 10...
AB Science annonce aujourd'hui que les résultats de l’étude AB12005 du masitinib dans le cancer du pancréas ont été présentés à la réunion annuelle 2021 de l'ASCO
June 10, 2021 12:54 ET | AB Science
COMMUNIQUE DE PRESSE PRESENTATION DES RESULTATS DE L’ETUDE AB12005 DU MASITINIB DANS LE CANCER DU PANCREAS A LA REUNION ANNUELLE DE L’ASCO ET PUBLICATION DU RESUME COMPLET DE L’ETUDE DANS LE...
Onconova Logo BLUE.jpg
Onconova Therapeutics Announces Participation in A.G.P.’s Upcoming Virtual Summer Healthcare Symposium
June 10, 2021 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
RevolutionLogo.png
Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors
June 10, 2021 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
Starton logo-pantone2112C.jpg
Starton Therapeutics to Present at 2021 BIO Digital
June 10, 2021 07:00 ET | Starton Therapeutics, Inc.
PARAMUS, N.J., June 10, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. announced today that it has been selected to deliver a company presentation at 2021 BIO Digital, the premier biotech event....
INNATEvertnoir.png
Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting
June 10, 2021 01:00 ET | INNATE PHARMA
Marseille, France, June 10, 2021 (GLOBE NEWSWIRE) -- Proprietary, multi-specific NK cell engager platform, ANKET™, to generate next wave of immunotherapy molecules ANKET is first NK cell engager...
INNATEvertnoir.png
Innate Pharma Presentera des Données Issues de sa Plateforme de NK Cell Engagers de Nouvelle Generation au Congrés Annuel de la FOCIS 2021
June 10, 2021 01:00 ET | INNATE PHARMA
Marseille, France, 10 juin 2021 (GLOBE NEWSWIRE) -- La plateforme propriétaire de NK cell engagers multi-spécifiques, ANKETTM, contribuera à générer une nouvelle vague de molécules...
Starton logo-pantone2112C.jpg
Starton Therapeutics Advances STAR-LLD Transdermal Lenalidomide Following Successful Skin Permeation Studies
June 09, 2021 08:00 ET | Starton Therapeutics, Inc.
PARAMUS, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary transdermal technology,...
New Logo.png
Provectus Biopharmaceuticals Announces Publication of In Vitro Data from Research on Oral Delivery of PV-10® at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
June 09, 2021 07:00 ET | Provectus Biopharmaceuticals Inc.
— PV-10 treatment induced autophagic cell death in all breast, colorectal, head and neck, and testicular cancer cell lines tested — Represents prerequisite in vitro data for clinical testing...